SAN JOSE, Calif., July 9, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (USPTO) will issue U.S. Patent Number 12,357,593 on July 15, 2025 covering key aspects of its ovarian cancer vaccine technology. The patent includes broad claims related to methods of eliciting an immune response targeting anti-Müllerian hormone receptor, ...

Core Viewpoint - Anixa Biosciences, Inc. is set to host an investor webcast on June 26, 2025, to discuss its business strategy, therapeutic portfolio, market opportunities, and upcoming milestones [1][2]. Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention [4]. - The company is developing an ovarian cancer immunotherapy program in collaboration with Moffitt Cancer Center, utilizing a novel CAR-T technology called chimeric endocrine receptor-T cell (CER-T) technology [4]. - Anixa's vaccine portfolio includes vaccines for breast and ovarian cancer developed with Cleveland Clinic, as well as additional vaccines targeting high incidence malignancies in lung, colon, and prostate cancers [4]. - The company partners with renowned research institutions to explore emerging technologies for development and commercialization [4]. Webcast Details - The webcast will feature an introductory presentation by Dr. Amit Kumar, Anixa's Chairman and CEO, followed by a Q&A session for investors [2]. - Interested participants must pre-register to listen to the webcast and ask questions during the live event [3].